Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
High-specificity killing of brain tumour cells using the Zika virus
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
Re-purposing diabetes medication to treat Ewing's sarcoma
Investigating repurposed drugs to decrease the progression of Ewing’s sarcoma
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Exploring a novel drug treatment for osteosarcoma
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Developing a ‘biodegradable paste’ to deliver chemotherapy directly to the brain to treat childhood brain tumours
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers